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AbsTrACT
background The Netherlands has a low hepatitis C 
virus (HCV) prevalence, estimated at 0.16%. Previous 
studies have shown that up to 30% of the diagnosed HCV 
population in the Netherlands has been lost to follow- up 
(LTFU). Retrieval of these patients could halt progression 
of liver disease in infected patients, reduce the number 
of infected individuals and limit HCV transmission. 
Several regional Dutch retrieval projects have already 
been executed, which demonstrated that retrieval is 
feasible. Therefore, we initiated a nationwide retrieval 
project, aiming to achieve microelimination in previously 
diagnosed but LTFU patients with chronic HCV through 
retrieval.
Methods Laboratory records will be used to identify 
possible patients with chronic hepatitis C, defined as 
either a positive most recent HCV RNA or positive HCV 
antibodies without known RNA result. Reviewing patient 
records and obtaining current contact information from 
municipality databases will identify LTFU patients who 
are eligible for retrieval. These patients will be invited 
for outpatient clinic care. The primary outcome of the 
study is the total number of LTFU patients who have been 
successfully linked to care.
Discussion Hepatitis C ELimination In the NEtherlands 
(CELINE) is within the remit of WHO elimination targets 
and the Dutch National Hepatitis Plan. The methodology of 
CELINE is based on previously conducted regional retrieval 
projects and is designed to overcome some of their 
limitations. After ethical approval was obtained in 2018, 
the first centre initiated retrieval in 2018 and the project is 
expected to finish in 2021.
Trial registration number NCT04208035.
InTroDuCTIon
Hepatitis C viral (HCV) infection is a major 
public health threat worldwide.1 It was esti-
mated that 71 million individuals were chron-
ically infected with HCV in 2015, causing 
399 000 deaths annually.2 3 After the intro-
duction of the highly effective direct- acting 
antivirals (DAAs), WHO adopted its Global 
Health Sector Strategy on viral hepatitis, 
setting the goal of global elimination of viral 
hepatitis as a public health threat by 2030.4 
Since then, numerous countries have started 
to plan measures in order to comply with 
WHO goals.
The Netherlands has a low HCV preva-
lence, estimated at 0.16%.5 The population 
in the Netherlands is 17 million and annually, 
approximately 300 people die as a result of 
HCV infection.6 HCV infections are mainly 
restricted to high- risk populations such as 
people who (formerly) inject(ed) drugs 
(PWID), immigrants from HCV endemic 
countries, people living with HIV, men who 
have sex with men (MSM) using pre- exposure 
HIV prophylaxis (PrEP) and people with 
inherited bleeding disorders.7–11 In the Neth-
erlands, the highest burden of HCV infec-
tion is among first- generation migrants.5 
Various measures to reach HCV elimination 
are already in place in the Netherlands. First, 
blood donors and MSM (if HIV positive or 
using PreP) are screened regularly. Further-
more, harm reduction strategies are avail-
able for PWID (opioid substitution therapy, 
needle exchange programmes) and MSM 
(eg, NoMoreC,12 an initiative in Amsterdam 
to increase awareness and HCV testing). As 
of November 2015, unrestricted DAA access 
is available in the Netherlands.13 DAAs are 
fully reimbursed by Dutch healthcare insur-
ance, with exception of the yearly obligatory 
deductible excess of €385. Healthcare insur-
ance is obligated for people residing in the 
Netherlands. However, asylum seekers, pris-
oners and homeless people are unfortunately 
unable to file for insurance. Healthcare 
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Figure 1 CELINE retrieval strategy. HCV, hepatitis C virus.
workers can in these cases request specific funding for 
DAA treatment, a lengthy and difficult process.
In 2016, a National Hepatitis Plan, including both hepa-
titis B and C, was developed, focusing on five key pillars 
of interest: (1) awareness and vaccination, (2) identifica-
tion of infected persons, (3) diagnostics and treatment, 
(4) improving care organisation and surveillance, and 
(5) monitoring the disease landscape. The current study 
falls under the second pillar.14
Previous studies have shown that up to 30% of the diag-
nosed HCV population in the Netherlands has been lost 
to follow- up (LTFU).15–18 Retrieval of these patients could 
both halt further progression of liver disease in infected 
patients and reduce the number of infected individuals 
through treatment and cure. Additionally, reducing 
the number of infected individuals serves as secondary 
prevention, by preventing ongoing transmission (treat-
ment as prevention). Several regional HCV retrieval 
projects have been executed in the Netherlands, which 
demonstrated that retrieval is feasible.15–17 Therefore, we 
initiated a nationwide retrieval project ‘Hepatitis C ELim-
ination In the Netherlands: CELINE’, based on the best 
practice methodology of these regional projects.
CELINE aims to microeliminate chronic hepatitis C in 
LTFU patients in all hepatitis centres in the Netherlands 
by retrieving and relinking them to care. Whereas the 
previously executed regional retrieval efforts successfully 
relinked 15% of LTFU patients to care,15–18 we hypoth-
esise that this optimised nationwide retrieval initiative 
could increase this number. Therefore, we aim to achieve 
a retrieval rate of 25% of patients LTFU and eligible for 
retrieval.
MeThoDs AnD AnAlysIs
study design
CELINE retrieval and re- evaluation efforts are part of 
regular care and serve no specific research purpose. 
Archived clinical data from retrieved patients will be 
collected and analysed for research purposes. There-
fore, CELINE is considered a multicentre observational 
cohort study.
setting
CELINE aims to cover all certified hepatitis treatment 
centres in the Netherlands. At the time of writing, there 
are 46 certified hospitals (both academic and non- 
academic), and names and location may be found at the 
website of the Netherlands Association for the Study of 
the Liver, which is constantly updated.19 Where possible, 
CELINE retrieval will be extended to other hospitals, 
Community Health Services, laboratories performing 
diagnostics for primary care and addiction centres. 
CELINE has started in 2018 and is scheduled to finish 
in 2021.
study population
CELINE aims to retrieve all LTFU patients with (possible) 
chronic HCV in the Netherlands in the 15- year period 
prior to collection of data. LTFU is defined as the lack 
of a scheduled future outpatient care appointment. 
Possible chronic hepatitis C is defined as the presence 
of persistent viremia (positive HCV RNA) or a positive 
antibody test without a known HCV RNA test at the 
time of LTFU. Patients are excluded from retrieval if 
their current address is unknown, if they are currently 
not living in the Netherlands, if they do not have health 
insurance or if HCV treatment is not indicated due to 
comorbidity or a short- life expectancy. Patients under 
18 years of age or unable or unwilling to give informed 
consent are not excluded from retrieval and may still be 
seen at the outpatient clinic. However, they will not be 
included in the core CELINE study.
retrieval strategy
The retrieval strategy of CELINE consists of four phases 
(see figure 1). In the first phase, the identification 
phase, electronic laboratory records will be used to iden-
tify patients that are (possibly) currently infected with 
chronic hepatitis C. These laboratory records contain 
all HCV diagnostic tests (HCV RNA, HCV antibodies, 
immunoblots and HCV genotype) performed in the 15 
years prior to start of data collection. This timeframe 
was chosen as healthcare providers are required by 
law to maintain their patient records for this period.20 
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However, daily practice varies, and therefore we aim 
to look back as far as possible. Subsequently, reviewing 
(electronic) patient records will exclude patients with 
a spontaneously cleared or cured infection, with severe 
comorbidity or limited life expectancy, those referred to 
another centre, still in outpatient care or patients who 
have been deceased. This results in a list of patients with 
a (possible) chronic HCV infection who are LTFU.
The next step involves consultation with the Munic-
ipal Personal Records Database (in Dutch: Basisregistratie 
Personen) to determine whether a patient is alive and if 
so, where they are currently residing. If the hospital in 
question is not authorised nor able to obtain authorisa-
tion to access these records, these data will be collected 
by contacting the patient’s general practitioner’s (GP) 
office. All patients in the Netherlands are attached to 
a GP office that serves as a portal to wider healthcare 
options. Patients who are LTFU, alive and with available 
current address information are defined as eligible for 
retrieval.
In the second phase of CELINE, patients eligible for 
retrieval will be contacted by a letter that provides addi-
tional information about hepatitis C and the new treat-
ment options. Patients will be invited for an outpatient 
clinic visit at a hepatitis centre close to their current resi-
dence. A reply card and return envelope will be enclosed 
with the letter in which a patient can explicitly give or 
withhold permission to be contacted by the researcher. 
If patients do not object, they will be contacted via tele-
phone by the coordinating researcher approximately 
2 weeks after receiving the letter. If patients do not wish 
to be contacted by the researcher, they can express this 
in the reply card, by telephone or via email. If we are 
unable to contact a patient after sending the letter, an 
attempt will be made to contact them via their GP or 
other concerned healthcare professionals.
The third phase is the core phase of CELINE and 
consists of re- evaluating retrieved patients. This outpa-
tient clinic visit is part of regular care and thus covered by 
health insurance. Patients will be asked by their treating 
physician/nurse specialist to sign the informed consent 
form for approval of further data collection. Patients who 
do not give informed consent can still re- enter regular 
care, but no data will be collected for research purposes. 
These patients are however counted as ‘retrieved’.
The fourth phase of CELINE is treatment and 
follow- up. The physician will discuss the results of the 
performed tests and determine a suitable treatment and/
or follow- up schedule, in accordance with current hepa-
titis C guidelines.21 The mandatory Dutch healthcare 
insurance fully reimburses DAA treatment, with excep-
tion of the obligatory deductible excess of €385 per year.
study outcomes
The primary outcome of CELINE is the total number of 
LTFU patients who have been successfully linked to care. 
Linkage to care is defined as having had at least one visit 
at the outpatient clinic of a registered hepatitis centre.
Secondary outcomes are:
 ► Total number of LTFU patients in the investigated 
time period.
 ► Case ascertainment rate, defined as established 
contact (via telephone or in writing) with a patient 
who is eligible for retrieval.
 ► Awareness of hepatitis C diagnosis among the LTFU 
patients.
 ► Percentage of patients who never had an outpatient 
clinic appointment with a hepatologist or infectious 
disease specialist after initial positive HCV test.
 ► Percentage of patients who are still viraemic (HCV 
RNA positive) at screening visit.
 ► Following patient and disease characteristics of the 
retrieved patients: liver fibrosis stage, reasons for 
becoming LTFU, time since last HCV related hospital 
visit, mode of HCV transmission and treatment 
outcome.
When liver fibrosis stage is assessed with Fibroscan 
(Echosens, Paris, France), the following cut- off values are 
used: ≤7.0 kPa for F0- F1 (no or mild fibrosis); 7.1–9.4 kPa 
for F2 (moderate fibrosis); 9.5–12.4 kPa for F3 (advanced 
fibrosis); and ≥12.5 kPa for F4 (cirrhosis).22
Data collection
Data of invited LTFU patients will be stored in a password- 
protected Excel file on the internal server of the hospital 
in question. This data can only be accessed by the local 
investigator and will remain confidential. Data of LTFU 
patients who signed informed consent will be entered 
into the database by the coordinating researcher after 
the patient has signed the informed consent form. It 
includes data on patient and disease characteristics, such 
as comorbidities, alcohol and drug use, country of birth, 
date of diagnosis, mode of transmission, HCV genotype, 
HCV RNA level, complications of chronic liver disease 
(cirrhosis, portal hypertension, ascites, hepatic enceph-
alopathy, varices/variceal bleeding and hepatocellular 
carcinoma) and treatment history. Furthermore, year 
of becoming LTFU, reason for LTFU, liver fibrosis stage 
according to Fibroscan, abdominal ultrasound results 
(organomegaly, portal vein characteristics, liver surface 
characteristics and presence of ascites or hepatocel-
lular carcinoma) and laboratory results (haemoglobin, 
thrombocytes, international normalized ratio (INR), 
estimated glomerular filtration rate (eGFR), alanine 
transaminase (ALT), aspartate transaminase (AST), 
gamma- glutamyltransferase (GGT), alkaline phosphatase 
(ALP), total bilirubin, albumin) will be collected. Year 
of LTFU is defined as the year of the last HCV- related 
hospital visit or the last HCV blood test.
Data management
Collected data will be encrypted; every patient will 
receive a unique code, which will be used for all study 
related documents and materials. Only the local prin-
cipal and coordinating investigators will have access to 
the local source file, in which the unique code is linked 
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to personal data such as name, gender and date of 
birth. A validated and GCP compliant data management 
program, CastorEDC, will be used for data storage.
statistical analysis
Descriptive data will be reported as either percentages, 
means (±SD) and medians (with IQR) when appropriate. 
Analyses will be performed using IBM SPSS Statistics 
V.25 (IBM Corp. Released 2017. IBM SPSS Statistics for 
Windows, V.25.0).
eThICs AnD DIsseMInATIon
ethical approval
The Research Ethics Committee (in Dutch: Commissie 
Mensgebonden Onderzoek, CMO) Arnhem- Nijmegen 
has ruled that CELINE does not include the Medical 
Research Involving Human Subjects Act (in Dutch: Wet 
Medisch- wetenschappelijk Onderzoek met mensen, WMO), 
and a non- WMO declaration has been provided in 2018. 
Each participating hospital has to provide local approval 
before CELINE can be initiated. Patients will be asked 
informed consent for registration of their coded data in 
the CastorEDC database by a member of the treatment 
team. Participation is voluntary and will not influence 
standard clinical care. The Code of Conduct for the Use 
of Data in Health Research will be taken into account.23
benefits and risks assessment
As a result of participation in this study, the LTFU popu-
lation could benefit from re- entry into the regular health-
care system. If patients still have an indication for and 
want to receive treatment, they can participate with all 
the benefits of the current treatment regimes. Further-
more, CELINE serves a population benefit by adhering 
to the treatment as prevention paradigm (reducing the 
pool of infected people by treating them limits trans-
mission of the disease). The minimal risks of this study 
(inconveniences of blood withdrawal, possibility of unex-
pected medical findings) do not outweigh this benefit.
DIsCussIon
Even though effective treatment is available and fully 
reimbursed in the Netherlands, with the exception of 
the obligatory deductible fee mentioned previously, up 
to 30% of the diagnosed HCV population is LTFU.15–18 
CELINE is a nationwide retrieval project which aims to 
achieve microelimination in previously diagnosed but 
LTFU patients with chronic HCV through retrieval and 
linkage to care. This project is within the remit of WHO 
elimination targets and the Dutch National Hepatitis 
Plan.4 14 24 The REtrieval And cure of Chronic Hepa-
titis C REACH) pilot study has shown that retrieval of 
LTFU patients with hepatitis C is feasible, although 
certain limitations accompanied the regional set- up of 
the study.18 We believe that the Netherlands is the right 
setting for CELINE due to the favourable HCV epide-
miology and access to DAA treatment. In addition, the 
Netherlands has an excellent infrastructure and high 
quality of healthcare.
We believe that microelimination, the concept of 
applying elimination targets to specific subpopulations,25 
is the preferred strategy for HCV elimination in coun-
tries with low HCV prevalence, such as the Netherlands.5 
An important subpopulation for microelimination are 
patients who are LTFU, as they are already diagnosed 
and spontaneous clearance of chronic HCV is rare.26 
Nonetheless, this population is rarely mentioned as a 
microelimination target population.25 27 This might be 
due to the fact that retrieval comes with many ethical and 
legal challenges, which we have described in detail else-
where.20 By showing that retrieval is feasible and bene-
ficial, we hope that CELINE can serve as an inspiration 
and a blueprint for other countries or regions to imple-
ment retrieval projects.
One of the strengths of CELINE is its methodology, 
which is based on several previously executed regional 
retrieval projects.15–18 These projects have shown that it is 
the best practice to identify LTFU patients by combining 
microbiology data with data from patient files. Medical 
microbiologists are allowed to share their data on HCV 
tests with hepatologists or infectious diseases specialists, 
since legally they are considered members of the treat-
ment team.28 Such legal and ethical challenges have been 
described in detail elsewhere.20 The regional retrieval 
studies preceding CELINE have identified a number of 
(logistical) obstacles which could threaten the execution 
of the project. One of the issues was that researchers were 
not allowed to retrieve patients outside of their study 
region, which limited their efficiency substantially. Also, 
even when this was allowed, significantly fewer patients 
who had moved outside the region were willing to visit 
the original retrieving centre, most often because of the 
geographical distance.18 Another problem was that in 
some projects, physicians were not allowed to contact 
patients directly. They had to be contacted by their GP, 
which resulted in multiple barriers: (1) GPs in the Neth-
erlands had to add another (unpaid) task to their already 
full agenda, which made response suboptimal, (2) many 
patients lacked updated GP information, which made it 
impossible to contact them at all and (3) most GPs are not 
HCV experts and therefore perhaps not fully equipped 
to adequately inform patients about treatment options. 
Therefore, within the remit of the CELINE project, 
patients are invited directly by the hospital physician, 
without direct interference of their GP. When a patient 
agrees to be re- evaluated, the GP is informed. We hypoth-
esise that this simplification, together with the nation-
wide aspect of CELINE, will result in a better retrieval 
(25%) compared with earlier efforts (<15%).15–18
One limitation of the CELINE project, and also of 
hepatitis C elimination in the Netherlands in general, 
is the lack of a national hepatitis C database. Such a 
database is currently being established and its devel-
opment might be facilitated due to the national 
collaboration network as is laid out through CELINE. 
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Furthermore, not all hepatitis treatment centres have 
authorisation to obtain current address information 
from municipalities. Address information in these 
cases has to be obtained from GPs. Similar to regional 
projects, the current GP might be unknown. Moreover, 
even with up- to- date address information, patients who 
do not respond to the retrieval letter cannot always be 
contacted because of an unknown telephone number. 
Another limitation is that patients are not compen-
sated for the payment of their yearly deductible excess 
fee of €385, which could result in patients refusing 
retrieval due to financial reasons. Finally, CELINE is a 
time- consuming project, which might make it difficult 
to translate to other healthcare environments that lack 
sufficient funding.
Relinkage to care will likely result in the patient being 
cured, which might prevent development or halt progres-
sion of liver disease. Furthermore, CELINE will result in 
a reduction of the pool of patients infected with HCV 
in the Netherlands, preventing further transmission. 
CELINE will also give insights into the hepatitis C cascade 
of care in the Netherlands. The project will provide 
numerous implications to improve patient care. An addi-
tional outcome of CELINE is a template for retrieval of 
LTFU patients with chronic hepatitis C that can be used 
and followed in other healthcare environments and/or 
countries.
To summarise, CELINE is a nationwide project that 
aims to retrieve and re- evaluate LTFU patients with 
chronic hepatitis C in the Netherlands. We aim to reduce 
liver disease burden for these patients and reduce further 
HCV transmission. The ultimate goal is to eliminate 
hepatitis C as a public health threat in the Netherlands, 
in accordance with WHO elimination targets.4 24
Trial status
After ethical approval was obtained in 2018, the first 
centre has initiated retrieval in 2018. So far, 14 centres 
have been included and 111 patients have been relinked 
to care. The study is still recruiting.
Author affiliations
1Department of Gastroenterology and Hepatology, University Medical Centre 
Utrecht, Utrecht, the Netherlands
2Division of Infectious Diseases, Amsterdam Infection & Immunity Institute 
Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
3Department of Gastroenterology and Hepatology, Erasmus MC University Medical 
Centre, Rotterdam, the Netherlands
4Department of Gastroenterology and Hepatology, Radboud University Medical 
Centre, Nijmegen, the Netherlands
5Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, the 
Netherlands
Twitter Marleen van Dijk @MarleenvanDijk_, Marc van der Valk @mvdvalk, Joop E 
Arends @jooparends and Joost PH Drenth @joostphdrenth
Acknowledgements The HepNed study groups consists of: Janke Schinkel, 
Amsterdam UMC location AMC; Sophie B. Willemse, Amsterdam UMC location AMC; 
Bart van Hoek, LUMC; Dirk Posthouwer, MUMC; David Burger, Radboudumc; Hans 
Blokzijl, University Medical Centre Groningen; Karel J. van Erpecum, University 
Medical Centre Utrecht.
Contributors All authors participated in design and execution of the study. CJI, 
SMB and MvD wrote the manuscript. MvdV, RJdK, JEA, JPHD, JS, BvH, DB and HB 
critically reviewed the manuscript.
Funding CELINE is supported with an unrestricted grant from Gilead Sciences.
Disclaimer Gilead Sciences does not have any role in study design, data 
collection, management, analysis and/or interpretation.
Competing interests CJI, SMB and MvD have no conflicts of interest. MvdV 
declares that the Amsterdam Infection & Immunity Institute Amsterdam UMC, 
on behalf of MvdV, received fees for participation in advisory boards of Abbvie, 
Gilead, Johnson & Johnson, Merck Sharp & Dohme (MSD), and ViiV and received 
independent research grants from Abbvie, Johnson & Johnson, Gilead, and 
MSD. RJdK declares that the Erasmus University Medical Centre, on behalf of 
RJdK, received honoraria for consulting/speaking from Gilead, Janssen- Cilag, 
Bristol- Myers Squibb (BMS), Abbvie, MSD, Roche, and Norgine and received 
research grants from Gilead, Janssen- Cilag, BMS, and Roche. JEA declares that 
the University Medical Centre Utrecht, on behalf of JEA, received honoraria for 
participation in advisory boards of Gilead, Janssen- Cilag, BMS, Abbvie, MSD, and 
ViiV and received research grants from BMS, Abbvie, and ViiV. JPHD declares that 
the Radboudumc, on behalf of JPHD, received honoraria or research grants from 
Novartis, Ipsen, Otsuka, Abbvie, and Gilead. JPHD served as consultant for Gilead 
and Abbvie, and in the last two years has been member of advisory boards of 
Otsuka, Norgine Gilead, BMS, Janssen, and Abbvie. JS participated in advisory 
boards of Gilead and received research grants from Gilead and Abbvie. SW has 
received honoraria for consulting/speaking from Gilead, Janssen- Cilag, BMS, and 
Roche, participated in advisory boards of Gilead, BMS, and Abbvie and received 
research grants from Gilead, Janssen- Cilag BMS, Abbvie, MSD, and Roche. BvH 
participated in advisory boards of Janssen- Cilag, BMS, Abbvie, MSD, and Norgine 
and received a research grant from Zambon Pharma. DP has no conflicts of 
interest to declare. DB has received honoraria for consulting/speaking from MSD, 
participated in advisory boards of MSD and received research grants from Gilead, 
Janssen- Cilag, BMS, MSD, and Roche. HB has participated in advisory boards of 
Gilead. KvE participated in advisory boards of Gilead, Janssen- Cilag, BMS, Abbvie, 
and MSD and received research grants from Gilead and Janssen- Cilag.
Patient consent for publication Not required.
ethics approval Formal ethical approval was waived in 2018 by the Research 
Ethics Committee Arnhem- Nijmegen as they ruled that CELINE does not fall within 
the Medical Research Involving Human Subjects Act. Local approval is obtained in 
each participating centre.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Future data are available upon reasonable request 
from the corresponding author.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCID iD
Marleen van Dijk http:// orcid. org/ 0000- 0001- 9092- 0481
reFerenCes
 1 Cooke GS, Andrieux- Meyer I, Applegate TL, et al. Accelerating 
the elimination of viral hepatitis: a Lancet Gastroenterology 
& Hepatology Commission. Lancet Gastroenterol Hepatol 
2019;4:135–84.
 2 World Health Organization. Global hepatitis report 2017. Geneva: 
World Health Organization, 2017.
 3 Polaris Observatory HCV Collaborators. Global prevalence and 
genotype distribution of hepatitis C virus infection in 2015: a 
modelling study. Lancet Gastroenterol Hepatol 2017;2:161–76.
 4 World Health Organization. Global health sector strategy on 
viral hepatitis 2016-2021: World Health organization;, 2016. 
Available: file:///X:/MDLZ/Users/research-artsen%20%20
promovendi/046362/Literatuur/ WHO% 20elimination% 20Global% 
20health% 20sector% 20strategy% 20on% 20viral% 20hepatitis% 
202016- 2021. pdf
 5 Koopsen J, van Steenbergen JE, Richardus JH, et al. Chronic 
hepatitis B and C infections in the Netherlands: estimated 
copyright.
 o
n
 April 28, 2020 by guest. Protected by
http://bmjopengastro.bmj.com/
BM
J O
pen G
astroenterol: first published as 10.1136/bmjgast-2020-000396 on 12 April 2020. Downloaded from 
6 Isfordink CJ, et al. BMJ Open Gastro 2020;7:e000396. doi:10.1136/bmjgast-2020-000396
Open access 
prevalence in risk groups and the general population. Epidemiol 
Infect 2019;147:e147.
 6 Hofman R, Nusselder WJ, Veldhuijzen IK, et al. Mortality due 
to chronic viral hepatitis B and C infections in the Netherlands] 
Sterfte aan chronische hepatitis B en C in Nederland. Ned Tijdschr 
Geneeskd 2016;160:D511.
 7 Schreuder I, van der Sande MA, de Wit M, et al. Seroprevalence 
of HIV, hepatitis B, and hepatitis C among opioid drug users on 
methadone treatment in the Netherlands. Harm Reduct J 2010;7:25.
 8 Fransen van de Putte DE, Makris M, Fischer K, et al. Long- Term 
follow- up of hepatitis C infection in a large cohort of patients with 
inherited bleeding disorders. J Hepatol 2014;60:39–45.
 9 European Centre for Disease Prevention and Control. 
Epidemiological assessment of hepatitis B and C among migrants in 
the EU/EEA. Stockholm: ECDC, 2016.
 10 Urbanus AT, Van De Laar TJW, Geskus R, et al. Trends in hepatitis 
C virus infections among MSM attending a sexually transmitted 
infection clinic; 1995-2010. AIDS 2014;28:781–90.
 11 Ghisla V, Scherrer AU, Nicca D, et al. Incidence of hepatitis C in HIV 
positive and negative men who have sex with men 2000-2016: a 
systematic review and meta- analysis. Infection 2017;45:309–21.
 12 NoMoreC. Available: https:// nomorec. nl/ en [Accessed 23 Mar 2020].
 13 Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced 
liver disease: outcomes and challenges. United European 
Gastroenterol J 2019;7:642–50.
 14 Hogenbirk RDS, van Steenbergen J, Urbanus A. Meer dan opsporen 
: Nationaal hepatitisplan: een strategie voor actie. 2016. RIVM 
rapport 2016-0166, 01-11-2016. Report No.: 2016-0166.
 15 Beekmans N, Klemt- Kropp M. Re- Evaluation of chronic hepatitis 
B and hepatitis C patients lost to follow- up: results of the Northern 
Holland hepatitis retrieval project. Hepatol Med Policy 2018;3:5.
 16 Spruijt AG, Wilting KR, Mithoe GD, et al. Tracing patients with 
chronic viral hepatitis] Opsporen van patienten met chronische 
virushepatitis. Ned Tijdschr Geneeskd 2016;160:D414.
 17 Wevers KVC PG, Hautvast JLA, Tostmann A, et al. Heropsporing 
van patiënten Met chronische hepatitis B en C. RIVM Infectieziekten 
Bulletin 2018;29.
 18 Kracht PAM, Arends JE, van Erpecum KJ, et al. Retrieval and cure of 
chronic hepatitis C (reach): results of micro- elimination in the Utrecht 
Province. Liver Int 2019;39:455-462.
 19 Nederlandse Vereniging voor Hepatologie (NVH). Hepatitis 
Behandelcentra. Available: https://www. hepatologie. org/ hepatitis- 
behandelcentra [Accessed 15 Nov 2019].
 20 van Dijk M, van Agt FM, Drenth J. Legal and ethical challenges in 
developing a Dutch nationwide hepatitis C retrieval project (CELINE). 
Int J Health Policy Manag 2020.
 21 European association for the study of the liver. electronic address eee, 
European association for the study of the L. EASL recommendations 
on treatment of hepatitis C 2018. J Hepatol 2018;69:461–511.
 22 Ledinghen Lédinghen V, Vergniol J. Transient elastography 
(FibroScan). Gastroenterol Clin Biol 2008;32:58–67.
 23 Federation of Dutch Medical Scientific Societies. The code of 
conduct for the use of data in health research 2004.
 24 World Health Organization. Combating hepatitis B and C to reach 
elimination by 2030. Geneva: World Health Organization, 2016.
 25 Lazarus JV, Wiktor S, Colombo M, et al. Micro- elimination - A path to 
global elimination of hepatitis C. J Hepatol 2017;67:665–6.
 26 Bulteel N, Partha Sarathy P, Forrest E, et al. Factors associated 
with spontaneous clearance of chronic hepatitis C virus infection. J 
Hepatol 2016;65:266–72.
 27 Lazarus JV, Safreed- Harmon K, Thursz MR, et al. The Micro- 
Elimination approach to eliminating hepatitis C: strategic and 
operational considerations. Semin Liver Dis 2018;38:181–92.
 28 Centrum voor infectieziektenbestrijding LCI/RIVM. Opsporing en 
herevaluatie van ooit gediagnosticeerden Met chronische hepatitis B 
en C 2016.
copyright.
 o
n
 April 28, 2020 by guest. Protected by
http://bmjopengastro.bmj.com/
BM
J O
pen G
astroenterol: first published as 10.1136/bmjgast-2020-000396 on 12 April 2020. Downloaded from 
